Ronald H. Lane, PhD
Founder & Executive Chairman
Neurobiologist and inventor of the SELtx platform. He led the foundational research and holds the issued and pending patents behind it.
Webinar on Zoom with the founder
Treating ALS Everyone went after the neuron. We went after the immune system.
More than two billion dollars has gone into ALS through the motor neuron. It has bought patients a few extra months. HOPE-Neuron built a non-drug medical device that filters and reprograms a patient’s immune cells.
- Date
- Tue, Oct 6, 2026
- Time
- 11:00 AM Pacific
- Length
- One hour, live Q&A
Ron Lane and Mark Forney
Founder and VP of Business Development
You're registered.
The Zoom link will arrive in your inbox before October 6. Add the hour to your calendar now so it doesn't slip.
Add to calendar
While you wait, the full offering statement lives on Republic. Reading it first makes for sharper questions.
Two ways to fight ALS. One has had a decade of funding.
Nearly every ALS program tries to protect the motor neuron directly. Ron Lane bet that the body's own immune response is doing much of the damage, and that you can change it without adding a drug.
The neuron route
$2B+
spent through the motor neuron. Patients got a few extra months.
- Mostly drug programs
- Treatments to date slow decline at best
- More than 100 active ALS trials still chasing a result
The HOPE-Neuron route
SELtx™
A patient's own blood, treated inside a patented device and returned.
- No drug added, no stem cells
- Targets the immune shift from attack mode to repair mode
- About 30 minutes, outpatient
A neurobiologist, a diagnosis, and ten years on the question the field skipped.
After his wife Sandy was diagnosed with Alzheimer's, Ron spent a decade and more than a million dollars of his own money asking something few labs were funded to ask: what if the immune system is part of the answer to neurodegeneration, and only part of the problem?
That work produced SELtx. The team has worked without salaries through the early years so the money could go to research.
10 yearsof founder-led research
$1M+of Ron's own money in
0drugs added to the blood
The untreated mice fell off the treadmill. The treated ones kept running.
p < 0.008
In a transgenic ALS mouse study at Indiana University School of Medicine, treated animals kept significantly more motor function than untreated ones, and the intended immune shift was statistically clear.
That is a mouse result. SELtx has never been tested in a person. The first human trial is what this raise is meant to fund, and it's the part of the story you should ask about on October 6.
Your hosts for the hour
What HOPE-Neuron has built, why the preclinical results encourage them, and where the company goes next.
Mark Forney
VP of Business Development
A Wall Street veteran and former biotech analyst and fund manager with more than four decades of experience. He leads partnerships and commercial strategy.
Come with the hard questions.
This isn't a sales pitch with a slide deck and no microphone. Ron and Mark will take these head on, and whatever else you bring.
What does the mouse data prove, and what does it not?
Ron answersWhy a device instead of a drug, and what does that change?
Ron answersWho are the clinical partners, and what are they waiting on?
Mark answersWhat happens if the first human study fails?
Both answer
Register for the webinar
Ron and Mark take questions live, so bring yours to the room.
Research and clinical partners
If you or someone you love has ALS
We're glad you found us. This session is about the company and its investment offering, and it won't be able to help anyone enroll in a trial or get treatment.
One hour on October 6. Bring the question you'd ask before investing.
The goal of this round is to fund the first human trial of SELtx. Hear the case from the people building it, then decide for yourself.